Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380:2225-2236.,Fischer K, Al-Sawaf O, Bahlo J, et al. Fixed-duration venetoclax plus obinutuzumab improves progression-free survival and minimal residual disease negativity in patients with previously untreated CLL and comorbidities. 24th Congress of EHA, abstract S149.
“EHA op afstand buitengewoon goed geregeld”
jul 2020